API General Cure

API General Cure is a widely available over-the-counter combination medication designed to treat a broad range of parasitic infections in freshwater aquarium fish. This popular medication combines two powerful active ingredients: metronidazole, an antiprotozoal and antibacterial agent effective against flagellated parasites and anaerobic bacteria, and praziquantel, an anthelmintic medication that targets flukes, tapeworms, and other flatworm parasites. The combination of these two complementary agents in a single product provides aquarists with a convenient and effective treatment option for many common parasitic diseases.

The mechanism of action of API General Cure reflects the distinct properties of its two active ingredients working through different pathways. Metronidazole enters susceptible organisms and undergoes reduction by intracellular electron transport proteins, generating cytotoxic compounds that damage DNA and other essential molecules, killing anaerobic bacteria and protozoans including Hexamita, Spironucleus, and the causative agents of hole-in-the-head disease. Praziquantel increases cell membrane permeability in susceptible parasites, causing calcium influx that leads to muscle contraction, paralysis, and eventual death of flukes, tapeworms, and related flatworm parasites. Together, these mechanisms address both single-celled protozoal parasites and more complex multicellular parasitic worms.

API General Cure is formulated as a water-soluble powder packaged in pre-measured packets for convenient dosing based on tank volume. Each packet is designed to treat 10 gallons of aquarium water, simplifying the calculation process for aquarists and reducing the risk of dosing errors. The powder dissolves readily when added to aquarium water, dispersing the medication throughout the tank. The product is specifically formulated for freshwater aquariums, though some aquarists have used it cautiously in brackish conditions under specific circumstances. The packaging includes clear instructions for treatment protocols.

The overall effectiveness and safety profile of API General Cure has made it a staple medication in many aquarists' fish medicine cabinets. The product has established a strong reputation for successfully treating conditions that were previously difficult for hobbyists to address without veterinary intervention, particularly hole-in-the-head disease in cichlids and discus. When used according to directions, most fish species tolerate the medication well, though the metronidazole component can affect biological filtration and invertebrate inhabitants. The combination approach reduces the need to correctly identify specific parasites before treatment, making it accessible for hobbyists without microscopy equipment.

API General Cure is primarily indicated for treating parasitic infections in freshwater aquarium fish, with particular effectiveness against protozoal parasites and flatworm infestations. The product is frequently used to treat hole-in-the-head disease (HITH, also called head and lateral line erosion or HLLE), a condition primarily affecting cichlids, discus, and some other species that causes characteristic pitting and erosion of the head and lateral line. While HITH has multiple contributing factors including water quality and nutrition, the protozoal parasites Hexamita and Spironucleus are often involved, and the metronidazole component of General Cure targets these organisms effectively.

Freshwater applications extend well beyond hole-in-the-head disease to encompass numerous parasitic conditions. Velvet disease (Oodinium), presenting as a dusty golden coating on fish that resembles fine powder, responds to the antiprotozoal action of metronidazole. Internal flagellate parasites causing white, stringy feces, loss of appetite, and wasting are targeted by the metronidazole component. Gill and body flukes (Dactylogyrus and Gyrodactylus species), identified by flashing, scratching, and respiratory distress, are eliminated by the praziquantel component. Intestinal tapeworms causing appetite changes and visible segments in feces are also targeted by praziquantel.

The combination nature of API General Cure makes it particularly valuable when aquarists observe nonspecific symptoms that could indicate various parasitic infections. Fish displaying general malaise, loss of appetite, color fading, increased mucus production, or behavioral changes such as hiding and reduced activity may be suffering from parasitic infections that are difficult to diagnose specifically without microscopic examination. In these cases, the broad-spectrum coverage of General Cure addresses multiple potential causes simultaneously, improving the likelihood of successful treatment when precise diagnosis is unavailable.

Secondary uses of API General Cure include quarantine treatment for new fish arrivals to eliminate parasites before introducing fish to established aquariums. This prophylactic application is particularly valuable when the origin and health history of new fish is unknown, such as with wild-caught specimens or fish from retailers with questionable sourcing. Some aquarists employ General Cure as part of a multi-step quarantine protocol, combining it with other medications to provide comprehensive pathogen elimination before fish join the main display tank.

When choosing API General Cure over single-ingredient medications, consider that this product excels when multiple parasite types may be involved, when diagnosis is uncertain, or when convenience of a pre-measured combination product is valued. However, aquarists who have positively identified a specific parasite may achieve more targeted treatment with single-ingredient medications. For example, if only flukes are present, praziquantel alone would suffice without the biological filter impact of metronidazole. Similarly, confirmed Hexamita infection could be treated with metronidazole alone. General Cure provides excellent broad coverage but comes with the trade-offs inherent to combination products.

The standard dosing protocol for API General Cure follows the manufacturer's straightforward recommendation of one powder packet per 10 gallons of actual aquarium water. It is essential to calculate dosing based on actual water volume rather than tank capacity, subtracting estimated displacement from substrate, decorations, equipment, and any water level below the tank rim. Accurate volume calculation prevents both underdosing, which may result in treatment failure, and overdosing, which increases stress on fish and beneficial bacteria. For tanks with volumes not evenly divisible by 10, erring slightly toward underdosing is generally safer than overdosing.

Tank treatment is the standard administration method for API General Cure, with the medication added directly to the aquarium after appropriate preparation. Before beginning treatment, remove all chemical filtration media including activated carbon, zeolite, and Purigen, as these will absorb the medication and reduce effectiveness. Maintain biological and mechanical filtration throughout treatment. Open the appropriate number of packets and dissolve the powder in a small container of tank water before adding to the aquarium, ensuring even distribution. Adding medication near a filter outflow or circulation pump helps distribute it throughout the tank.

The complete treatment protocol specified by API consists of two doses administered 48 hours apart, followed by a 25% water change before the second dose and a 25% water change 48 hours after the second dose to conclude treatment. This schedule allows medication exposure during the most vulnerable stages of parasite life cycles. During treatment, maintain normal lighting schedules, though slightly reduced photoperiods may decrease fish stress. Continue feeding normally with high-quality foods to support fish immune function and recovery, though reduce quantities slightly if water quality parameters begin to deteriorate.

Treatment duration with API General Cure is relatively brief compared to some aquarium medications, with the complete protocol spanning approximately 4-5 days. For persistent infections that do not resolve after a single treatment course, a second complete course may be administered after a recovery period of 5-7 days between courses. Do not exceed two treatment courses without reevaluating the diagnosis, as repeated treatment failure may indicate misdiagnosis, antibiotic-resistant organisms, or underlying conditions requiring different approaches. Visible improvement in symptoms such as reduced flashing, restored appetite, or clearing of visible parasites typically appears within the first treatment course.

Water changes during treatment follow the manufacturer's protocol: perform a 25% water change between the first and second doses, and another 25% water change 48 hours after the second dose to complete treatment. These water changes serve multiple purposes, including removal of dead parasites and their waste products, restoration of water quality potentially degraded by treatment, and removal of medication at appropriate treatment stages. Use dechlorinated water matched to tank temperature and carefully preserve biological filtration bacteria, which may be stressed by metronidazole exposure.

Redosing after water changes follows the schedule above, with the second dose applied immediately following the between-dose water change. If significant water changes beyond the recommended 25% become necessary during treatment due to water quality issues, proportional medication replacement may be considered to maintain therapeutic levels, though this should be approached cautiously to avoid overdosing. After completing treatment, perform an additional larger water change of 50% or more and replace chemical filtration media to remove any residual medication from the system before returning the tank to normal operation.

The effects of API General Cure on fish are generally well-tolerated when the product is used according to label directions, though some individuals may exhibit mild stress responses during treatment. Common observations during treatment include temporary reduction in appetite, which typically resolves as treatment concludes, and slightly reduced activity levels as fish respond to medication and ongoing parasite elimination. Some fish may show temporary color fading or darkening depending on species; this usually resolves within days of completing treatment. Most healthy fish tolerate the complete treatment course without significant adverse effects, though stressed or severely ill fish may show more pronounced reactions.

The metronidazole component of API General Cure significantly impacts biological filtration, representing one of the most important considerations when using this product. Metronidazole is effective against anaerobic bacteria, and while nitrifying bacteria are primarily aerobic, the medication can still affect bacterial populations in lower-oxygen zones of filter media and substrate. Ammonia and nitrite spikes during or following treatment are common, requiring diligent monitoring and readiness to perform additional water changes. Consider reducing feeding during treatment to minimize waste production, and have ammonia-neutralizing products available for immediate use if nitrogen compounds begin accumulating.

Live aquarium plants generally tolerate API General Cure treatment without significant adverse effects, as neither metronidazole nor praziquantel targets plant-specific pathways. However, any disruption to the nitrogen cycle may indirectly affect plant health through ammonia toxicity or altered nutrient availability. Plants may show reduced growth during treatment but typically recover quickly afterward. Heavily planted tanks may actually benefit from slightly increased water changes during treatment to maintain optimal conditions for both plants and fish while managing the biological filtration impact.

Invertebrates are significantly affected by API General Cure, and the manufacturer clearly warns against use in tanks containing snails, crabs, or shrimp. Praziquantel is broadly toxic to invertebrates due to its mechanism affecting cell membrane permeability, and metronidazole poses additional risks. Snails of all species are particularly vulnerable to praziquantel and frequently die during or following treatment. Ornamental shrimp including Neocaridina and Caridina species cannot tolerate General Cure and must be removed before treatment. Any invertebrates present in tanks requiring treatment should be relocated to a separate untreated system for the duration of treatment and recovery period.

Water appearance changes during API General Cure treatment are minimal compared to some other aquarium medications. The powder dissolves relatively clearly without significantly coloring the water, though slight cloudiness may occur as the medication disperses and during bacterial die-off. Any significant clouding, milky appearance, or foul odors suggest water quality problems requiring immediate water change intervention. The tank may temporarily show increased organic matter including shed parasite material and mucus; this is normal and should clear with filtration and the post-treatment water changes.

API General Cure is explicitly contraindicated for use in aquariums containing invertebrates, as clearly stated on the product label. This includes all snail species, which are extremely sensitive to the praziquantel component and will almost certainly die during treatment. Shrimp of all types including cherry shrimp, Amano shrimp, ghost shrimp, and any Caridina species cannot tolerate this medication. Freshwater crabs, crayfish, and freshwater clams or mussels similarly must not be exposed to General Cure. Before treatment, all invertebrates must be relocated to separate untreated systems, or an alternative treatment approach must be selected.

Certain fish species may show enhanced sensitivity to API General Cure components, though specific contraindications are less clearly established than for invertebrates. Scaleless fish including loaches and many catfish species may absorb medication more readily and should be observed carefully during treatment, with consideration given to slightly reduced dosing if permitted by the severity of infection. Very small or delicate fish species, including recently hatched fry, may not tolerate full treatment protocols. Species known to be sensitive to medications in general, such as elephant nose fish and certain wild-caught species, warrant extra caution and observation.

Marine and reef aquariums should never be treated with API General Cure, which is formulated specifically for freshwater systems. Beyond the invertebrate toxicity that would devastate reef inhabitants, the medication has not been tested for marine applications and may behave differently in saltwater chemistry. Marine fish requiring treatment for comparable parasitic infections should be moved to a freshwater-appropriate hospital tank or treated with marine-specific medications. Brackish water systems present intermediate challenges; while some aquarists have used General Cure cautiously in low-end brackish conditions, this represents off-label use with unpredictable results.

API General Cure should not be used casually or prophylactically without reasonable suspicion of parasitic infection. The impact on biological filtration and the necessity of removing invertebrates makes this a medication to deploy with purpose rather than as a precautionary measure. Using General Cure "just in case" exposes fish to unnecessary medication stress, disrupts the nitrogen cycle without benefit, and contributes to potential resistance development. Reserve this medication for situations where parasitic infection symptoms are present, when new fish with unknown health history require quarantine treatment, or when veterinary guidance indicates its use.

API General Cure should not be combined simultaneously with other medications during active treatment, as unpredictable interactions may occur and the biological filter is already stressed by the metronidazole component. Adding additional medications, particularly antibiotics, compounds the impact on beneficial bacteria and may cause complete filter failure. The combination of metronidazole and praziquantel in General Cure is already formulated to address multiple parasite types; adding further medications during the treatment course is rarely beneficial and often counterproductive. If multiple conditions require treatment, sequential approaches with adequate recovery periods between medications are preferable.

Sequential treatment considerations following API General Cure should account for the medication's effects on fish and filter before adding subsequent treatments. A minimum recovery period of 5-7 days following General Cure completion is advisable before beginning treatment with other medications, allowing fish to destress and biological filtration to stabilize. Water changes during this recovery period help remove residual medication and restore water quality. If additional treatment is needed for conditions not addressed by General Cure, such as bacterial infections requiring antibiotics, waiting for this recovery period optimizes treatment success and reduces cumulative stress.

Water conditioner interactions with API General Cure are generally minimal, allowing normal use of dechlorinating products during treatment. Standard water conditioners can be added to replacement water during the required water changes without affecting medication efficacy. However, products containing additional ingredients such as stress coat formulations, ammonia binders, or heavy metal chelators should be used cautiously. Adding these products to treatment water may theoretically interact with medication stability, though specific interactions are not well-documented. The conservative approach involves using basic dechlorinators only during active treatment.

Safe supportive measures during API General Cure treatment include salt additions at low concentrations (1-2 ppt) for osmoregulatory support, increased aeration to maintain oxygen levels, and slightly elevated temperatures within species-appropriate ranges to support immune function. These measures do not interact with the medication and may improve treatment outcomes. Vitamin supplements, particularly vitamin C and garlic-based products reported to support immune function, can be added to food during treatment. Beneficial bacteria supplements added after treatment completion may help accelerate biological filter recovery.

Removal of activated carbon and chemical filtration media before beginning API General Cure treatment is absolutely essential and cannot be overemphasized. Carbon rapidly absorbs both metronidazole and praziquantel, potentially rendering treatment ineffective within hours of dosing. All chemical media including carbon, zeolite, Purigen, and phosphate removers must be removed before the first dose. Mark removed media for disposal after treatment, as attempting to reuse media that has absorbed medication may result in medication release back into the tank at unpredictable levels. Replacement chemical media should only be added after treatment completion and post-treatment water changes.

Biological filtration protection requires proactive monitoring throughout API General Cure treatment and extending into the recovery period. Test ammonia and nitrite levels before treatment to establish baseline values, then monitor daily during treatment and for at least one week following treatment completion. The metronidazole component will likely affect bacterial populations, and ammonia spikes commonly occur between day 3 and day 7 of the treatment and recovery timeline. Have water change supplies prepared and ammonia-neutralizing products on hand. Reduce feeding during treatment and recovery to minimize nitrogen waste production. Consider adding beneficial bacteria products after treatment to accelerate filter recovery.

UV sterilizers should be turned off during API General Cure treatment to prevent ultraviolet light from degrading the medication. UV exposure breaks down both metronidazole and praziquantel, reducing their effectiveness and requiring higher or more frequent dosing. Additionally, UV sterilization kills microorganisms indiscriminately, adding pressure on already-stressed beneficial bacterial populations. The UV unit can be reactivated after treatment completion and water changes, potentially helping control opportunistic organisms during the recovery period while biological filtration stabilizes.

Adequate aeration during treatment supports fish dealing with infection, medication stress, and potentially compromised water quality. Parasitic infections often affect gill function, increasing oxygen requirements, while any ammonia accumulation further stresses respiratory systems. Ensure surface agitation is sufficient for gas exchange, and consider adding supplemental aeration through air stones or increased powerhead flow. Monitor fish for signs of oxygen stress including rapid gill movement, gasping at the surface, or congregating near filter outflows. Heavily stocked tanks and warmer water temperatures increase oxygen demands.

Human safety considerations when handling API General Cure include avoiding direct skin contact and inhalation of the powder during preparation. While neither metronidazole nor praziquantel is highly toxic to humans at these concentrations, unnecessary exposure should be avoided. Metronidazole can cause metallic taste and nausea if ingested, and both components may cause skin irritation in sensitive individuals. Wash hands thoroughly after handling medication packets and avoid touching face or eyes before washing. Store medication securely away from children and pets. Do not use in tanks providing fish for human consumption.

API General Cure should be stored according to standard pharmaceutical guidelines in a cool, dry location away from direct light and extreme temperatures. The ideal storage temperature range is 59-77°F (15-25°C), avoiding areas subject to temperature fluctuations such as bathrooms, garages, or locations near heat sources. Keep packets in their original packaging until ready for use, as the foil packets protect the powder from moisture absorption and light exposure that can degrade active ingredients. Store away from food preparation areas and out of reach of children and pets.

Shelf life of API General Cure extends several years when stored properly in unopened original packaging, with expiration dates printed on packaging providing specific guidance. Once packets are opened, any unused powder should be used promptly or discarded, as exposure to air and humidity accelerates degradation. Do not attempt to store partially used packets for future use; the difficulty of measuring precise partial doses and the uncertain stability of exposed powder makes this practice unreliable. Discoloration, unusual odor, or clumping of powder indicates degradation, and affected product should be replaced rather than used.

Safe disposal of unused API General Cure and treatment water follows standard aquarium medication guidelines. Do not flush medication down toilets or drains, as pharmaceutical compounds entering waterways can affect aquatic ecosystems and potentially contribute to antimicrobial resistance in environmental bacteria. Unused packets should be opened and powder mixed with undesirable material such as coffee grounds or cat litter, sealed in a container, and disposed with regular household trash. Treatment water contains dilute medication and should be disposed down household drains connected to sewer or septic systems rather than into storm drains or natural waterways. Some areas offer pharmaceutical take-back programs providing environmentally responsible disposal options.

Freshwater community fish species generally tolerate API General Cure well at standard dosing, making it suitable for treating mixed-species tanks. Tetras, barbs, rasboras, and other common community species typically complete treatment without significant adverse effects. Livebearers including guppies, mollies, platies, and swordtails similarly tolerate standard protocols. Goldfish and other coldwater species can be treated with General Cure, though treatment at lower temperatures may require extended duration as parasite life cycles slow in cooler water. Bettas tolerate the medication well and benefit from treatment of common parasites including velvet and intestinal flagellates.

Cichlid species, particularly those prone to hole-in-the-head disease, represent a primary target population for API General Cure treatment. African cichlids including mbuna, peacocks, and haps frequently develop HITH and respond well to the metronidazole component. South American cichlids including oscars, severums, and geophagus similarly benefit from treatment. Discus, though more sensitive than some cichlids, can be treated with standard dosing when suffering from Hexamita or Spironucleus infections, with careful monitoring for stress responses. Angelfish tolerate treatment well and often benefit from prophylactic treatment during quarantine.

Scaleless and semi-scaleless fish species require careful observation during API General Cure treatment, though specific dose reductions are not typically necessary with this medication. Clown loaches, kuhli loaches, and weather loaches should be monitored for signs of distress but generally complete treatment successfully at standard doses. Corydoras catfish and other armored catfish similarly tolerate normal protocols. Plecos and other suckermouth catfish can be treated normally. However, if signs of distress develop in scaleless species, water changes to reduce medication concentration may be necessary, and treatment may need to be discontinued before completion in sensitive individuals.

Species-specific considerations extend to dietary and behavioral factors affecting treatment success. Bottom-dwelling species may receive higher medication exposure through substrate contact during tank treatment; this is generally not problematic at standard doses but reinforces the importance of accurate dosing. Species that are reluctant to eat during illness pose challenges for any treatment relying on appetite maintenance for nutritional support; these fish benefit from particularly careful water quality management to reduce additional stress. Sensitive species including elephant nose fish and some wild-caught specimens may require conservative approaches with enhanced monitoring.

Within the combination medication category, API General Cure can be compared to other products offering multi-pathogen coverage. API Fin and Body Cure combines metronidazole with the antibiotic doxycycline, providing coverage against both parasites and bacterial infections but lacking the fluke-targeting praziquantel component. Seachem ParaGuard offers an aldehyde-based approach to external parasites but does not address internal parasites or flukes. Fritz Paracleanse provides similar praziquantel coverage for flukes and worms without the metronidazole antiprotozoal component. Understanding the specific components of combination products allows selection of the most appropriate medication for identified or suspected conditions.

Single-ingredient alternatives allow more targeted treatment when specific parasites have been identified. Pure metronidazole (Seachem Metroplex, API General Cure's primary component sold separately) can treat Hexamita, Spironucleus, and other protozoal parasites without the broader effects of the combination product. Pure praziquantel (API General Cure's second component available separately, also found in products like Prazipro) addresses flukes and tapeworms specifically. When microscopic examination or other diagnostic methods have confirmed the specific parasite type, these targeted treatments may be preferred, particularly when biological filter impact or invertebrate safety concerns make the combination product problematic.

Combination treatment strategies sometimes employ API General Cure as one component of a broader treatment protocol. Following General Cure treatment for parasitic infections, bacterial infections that often accompany or follow parasitic damage may require subsequent antibiotic therapy. The product can be used in sequence with antibiotics like Kanaplex or Maracyn 2 for comprehensive pathogen elimination during quarantine, with appropriate recovery periods between treatments. Some advanced protocols combine General Cure with mild antibacterial medications like Methylene Blue, though simultaneous use of multiple medications increases treatment complexity and should be approached cautiously.